Compare Prologis Inc (PLD) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prologis Inc vs Revvity Inc — how do they compare? Prologis Inc trades at $136.97 (market cap $131.60B), while Revvity Inc trades at $124.14 (market cap $14.18B). The key difference: Prologis Inc is far larger — about 9.3× Revvity Inc's market cap, and Prologis Inc pays the higher dividend (3.09%). Which is the better fit depends on your goals.
| PLD | RVTY | |
|---|---|---|
Market Cap | $131.60B | $14.18B |
Sector | Real Estate | Technology |
52-Week High | $149.96 | $130.94 |
52-Week Low | $110.98 | $82.26 |
Enterprise Value | $166.34B | $16.50B |
Dividend Yield | 3.09% | 0.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prologis (PLD) trades at $138.49, up 0.84% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.13 exceeding the $0.747 estimate. Revenue grew to $8.79 billion in 2025, though net income margin dipped to 37.86%. The stock faces headwinds from a high P/E of 30.84 and rising debt-to-asset ratio, now at 37.2% for 2025. Recent news highlights institutional buying interest amid market volatility.
The outlook for PLD is mixed, with analyst consensus bullish (59.52% buy ratings) and a $160.13 price target suggesting 15.6% upside. Key opportunities include sustained revenue growth and dividend stability, but risks involve elevated valuation, debt levels, and macroeconomic sensitivity. The stock's performance hinges on Q3 2026 earnings and the integration of the SEGRO acquisition.
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
